Efficacy of the use of the immunomodulator “thymocin” in disseminated breast cancer
https://doi.org/10.52888/0514-2515-2024-360-1-34-39
Abstract
Aim. To study the efficacy of the use of the immunomodulator «Thymocin» in patients with disseminated breast cancer.
Material and Methods. The subject of the study were 36 patients with disseminated breast cancer observed in the conditions of the Department of Mammology and Reconstructive Plastic Surgery and the Department of Chemotherapy of the SI «Republican Cancer Research Center» of the MHSPP of Tajikistan. All patients were prescribed the immunomodulatory drug «Thymocin».
Research results. With the use of Thymocin in patients, indicators of immunity returned to normal, an increase in the concentration of β-endorphin was observed. The physical condition of patients with disseminated breast cancer also improved, as assessed by the modified Karnovsky scale.
Conclusions. The use of thymocin immunomodulator in the complex therapy of patients with BC does not require large material costs, special equipment or tools, is cost-effective and affordable. Does not have toxic properties, can significantly reduce the threshold of pain sensitivity in patients with a generalized tumor process, thereby improving the quality of life of these patients.
About the Authors
D. S. Mirzoeva
State Institution «Republican Cancer Research Center» MH SPP RT
Tajikistan
Tajikistan
Mirzoeva Dilorom Sattorovna - Doctor of Medical Sciences, doctor of the highest category, mammologist.
L. A. Sufiev
State Institution «Republican Cancer Research Center» MH SPP RT
Tajikistan
Tajikistan
S. G. Radjabova
State Institution «Republican Cancer Research Center» MH SPP RT
Tajikistan
Tajikistan
References
1. Vazhenin A.V. Klinicheskiy rezultat dlitelnogo kontrolya zabolevaniya pri her-2 polozhitelnom disseminirovannom rake molochnoy zhelezy s metastazami v golovnoy mozg u patsientki fertilnogo vozrasta [Clinical outcome of long-term disease control in her-2 positive disseminated breast cancer with brain metastases in a fertile patient]. Sibirskiy onkologicheskiy zhurnal - Siberian journal of oncology, 2021, No. 20 (3), pp. 158-164.
2. Mirzoeva D.S. Znachenie immunoterapii v palliativnom lechenii bolnykh disseminirovannym rakom molochnoy zhelezy [The significance of immunotherapy in the palliative treatment of patients with disseminated breast cancer]. Meditsinskiy vestnik Natsionalnoy akademii nauk Tadzhikistana - Medical Bulletin of the National Academy of Sciences of Tajikistan, 2017, No. 2 (22), pp. 35-38.
3. Slepov Yu.K. Gipoteza o roli immunnoy sistemy v kantserogeneze [Hypothesis of the role of the immune system in carcinogenesis]. Geny i kletki - Genes and cells, 2021, Vol 16, No. 1, pp. 82-91.
4. Emery M.A. Endogenous opioids at the intersection of opioid addiction, pain, and depression: the search for a precision medicine approach. Annual Review of Neuroscience, 2020, No. 43, pp. 355–374.
5. Gosain R. Stress reduction strategies in breast cancer: review of pharmacologic and non-pharmacologic based strategies. Seminars in Immunopathology, 2020, No. 42 (6), pp. 719-734.
6. Mutebi M. Breast cancer treatment: A phased approach to implementation. Cancer, 2020, No. 126 (10), pp. 2365-2378.
7. Shi D. Thymic function affects breast cancer development and metastasis by regulating expression of thymus secretions PTMα and Tβ15b1. Translational Oncology, 2021, No. 1 (14), pp. е100980.
Review
For citations:
Mirzoeva D.S., Sufiev L.A., Radjabova S.G. Efficacy of the use of the immunomodulator “thymocin” in disseminated breast cancer. Health care of Tajikistan. 2024;(1):34-39. (In Russ.) https://doi.org/10.52888/0514-2515-2024-360-1-34-39
Views:
281
Email this article 